TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10941955
Drug: Feedback on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feedback on asthma treatment
Study: 10941955
Drug: Feedback on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feedback on UTI treatment
Study: 8814852
Drug: Sexual-hormone binding
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sexual-hormone binding globulin (SHBG)
Study: 12512664
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no early treatment)
Study: 9082830
Drug: Microvessel count
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microvessel count (MC) assessed using JC70 monoclonal antibody (CD31)
Study: 1796618
Drug: Prednisolone-pulse-therapy
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone-pulse-therapy
Study: 6828842
Drug: Acetazolamide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (2 X 250 mg)
Study: 6828842
Drug: Long-term Acetazolamide
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term Acetazolamide therapy
Study: 26254255
Drug: rTMS combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS combined with comprehensive rehabilitation therapy
Study: 26254255
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy combined with comprehensive rehabilitation therapy
Study: 18251624
Drug: Olanzapine (2.5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (2.5-15 mg/day)
Study: 11008913
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HPV and LSIL cutpoint
Study: 3884297
Drug: Injection sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection sclerotherapy with phenol (N = 62)
Study: 24155093
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (SB) supplementation at 0.3 g/kg body mass
Study: 18408607
Drug: CHO (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (0.8 g.kg(‐1)h(‐1) of carbohydrate)
Study: 18408607
Drug: CHO‐PRO (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO‐PRO (0.8 g.kg(‐1)h(‐1) of carbohydrate + 0.3 g.kg(‐1)h(‐1) of whey protein isolate)
Study: 16161728
Drug: Levo‐alpha‐acetylmethadol (LAAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levo‐alpha‐acetylmethadol (LAAM) treatment
Study: 16161728
Drug: Community treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community treatment referral information only (Control)
Study: 16161728
Drug: Withdrawn from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawn from treatment (Control)
Study: 8777484
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral administration of propafenone
Study: 3294945
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil 2% solution applied twice daily with UVB treatment
Study: 3294945
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil 2% solution applied twice daily with PUVA treatment
Study: 3294945
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil 2% solution applied twice daily without UVL
Study: 29649309
Drug: Lopinavir/ritonavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir monotherapy (MT)
Study: 24041682
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living (3 bouts of 15 min, ∼3 METs)
Study: 17531401
Drug: Whole pelvic
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole pelvic radiotherapy (WPRT) + Neoadjuvant hormonal therapy (NHT)
Study: 17531401
Drug: Prostate only
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate only radiotherapy (PORT) + Neoadjuvant hormonal therapy (NHT)
Study: 17531401
Drug: Whole pelvic
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole pelvic radiotherapy (WPRT) + Adjuvant hormonal therapy (AHT)
Study: 17531401
Drug: Prostate only
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate only radiotherapy (PORT) + Adjuvant hormonal therapy (AHT)
Study: 17531401
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal therapy (NHT) + Radiotherapy (RT)
Study: 10901187
Drug: Urinary thymidine
Normalized name: Thymidine
DrugBank: Thymidine (DB04485)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary thymidine glycol excretion after kidney transplantation
Study: 10901187
Drug: Gel-electrophoretic pattern
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel-electrophoretic pattern of proteinuria
Study: 10901187
Drug: Thymidine glycol
Normalized name: Thymidine
DrugBank: Thymidine (DB04485)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymidine glycol excretion levels during different phases
Study: 2694860
Drug: Suction on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suction on the tubes with a 60‐ml syringe
Study: 15760
Drug: Beta-adrenoreceptor antagonists
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenoreceptor antagonists (specific drugs not mentioned)
Study: 31398157
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous fluids before surgery (study group, 90 patients)
Study: 31398157
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml crystalline intravenous fluids one hour before anaesthesia (control group, 90 patients)
Study: 23814850
Drug: R-CHOP (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP (standard treatment)
Study: 20633187
Drug: Rabeprazole-based quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole-based quadruple rescue therapies (RB)
Study: 20633187
Drug: Esomeprazole-based quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole-based quadruple rescue therapies (EB)
Study: 6994783
Drug: Guanfacine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine 1.0 mg and 2.0 mg
Study: 6994783
Drug: Clonidine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.15 mg and 0.3 mg
Study: 30650500
Drug: Alendronate sodium
Normalized name: Alendronate Sodium
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate sodium 70 mg each week
Study: 25085304
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Transbond XT; 3M Unitek)
Study: 19557208
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg once daily added to ICS or ICS/LABA therapy
Study: 18372683
Drug: Intermittent artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent artificial gravity (AG) via short radius centrifugation (SRC) for 60 min daily during bed rest
Study: 12059822
Drug: Midazolam 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.02 mg.kg(‐1)
Study: 12059822
Drug: Propofol 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.25 mg.kg(‐1)
Study: 8583658
Drug: Amrinone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone 0.5 mg.kg‐1 administered in the venous reservoir near the end of cardiopulmonary bypass (CPB) and doses of 1 and 5 micrograms.kg‐1.min‐1 by intravenous infusion
Study: 6268475
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (21 g/day in three divided doses at main meals)
Study: 27560946
Drug: HCP0911 (fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCP0911 (fixed-dose combination of clopidogrel and aspirin)
Study: 27560946
Drug: Separate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate treatment with daily 75 mg clopidogrel plus 100 mg aspirin
Study: 22617861
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) at a target dose of 1.2 mg/kg per day
Study: 12440843
Drug: Anthroposophical herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthroposophical herbal remedy (20 drops 4 times daily for 4 weeks)
Study: 2373128
Drug: Org 3770
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 3770 (30 mg)
Study: 22551440
Drug: Adjuvant doxorubicin-based
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant doxorubicin-based chemotherapy with or without docetaxel
Study: 9678794
Drug: G-CSF 6
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF 6 microg/kg/12 h
Study: 9678794
Drug: G-CSF 8
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF 8 microg/kg/12 h
Study: 30279273
Drug: Urinary DKK3-to-creatinine
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary DKK3-to-creatinine level >4000 pg/mg
Study: 26580997
Drug: ALS-008176 (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALS-008176 (750 mg loading dose followed by 500 mg maintenance doses)
Study: 26580997
Drug: ALS-008176 (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALS-008176 (750 mg loading dose followed by 150 mg maintenance doses)
Study: 26580997
Drug: ALS-008176 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALS-008176 (10 doses of 375 mg)
Study: 26580997
Drug: ALS-008176 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALS-008176 (all groups with loading dose)
Study: 20622695
Drug: Lipostabil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipostabil (0.5 ml injected in one eyelid)
Study: 20622695
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (0.5 ml injected in the opposite eyelid)
Study: 18461520
Drug: 5-aminosalicylates (sulphasalazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-aminosalicylates (sulphasalazine 2 g/d)
Study: 18461520
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition at home
Study: 10595624
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg per day)
Study: 8919898
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg eltanolone
Study: 8919898
Drug: 0.75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/kg eltanolone
Study: 8919898
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg eltanolone
Study: 8919898
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg thiopentone
Study: 1812137
Drug: L-tryptophan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (50 mg/kg of body weight)
Study: 6305758
Drug: Intravenous corticotropin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous corticotropin (120 U/day)
Study: 6305758
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone (300 mg/day)
Study: 30658605
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of 10 IU oxytocin
Study: 30658605
Drug: IM injection
Normalized name: filgrastim Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM injection of 10 IU oxytocin
Study: 26672898
Drug: Dabigatran (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (150 mg twice-daily)
Study: 26672898
Drug: Dabigatran (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (110 mg twice-daily)
Study: 26672898
Drug: Rivaroxaban (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (20 mg once-daily)
Study: 26672898
Drug: Rivaroxaban (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (15 mg once-daily)
Study: 26672898
Drug: Apixaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (5 mg twice-daily)
Study: 26672898
Drug: Apixaban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (2.5 mg twice-daily)
Study: 22549097
Drug: Dispersible levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible levodopa/carbidopa microtablets (LC-5), 5/1.25 mg
Study: 22549097
Drug: Standard levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard levodopa/carbidopa (LC-100), 100/25 mg
Study: 22549097
Drug: Dispersible levodopa/benserazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible levodopa/benserazide (LB-100), 100/25 mg
Study: 22549097
Drug: Carbidopa (from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa (from all formulations)
Study: 22549097
Drug: 3-O-MD (from
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-O-MD (from all formulations)
Study: 10761164
Drug: Effervescent acetaminophen
Normalized name: acetaminophen Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent acetaminophen 1000 mg
Study: 10761164
Drug: Tablet acetaminophen
Normalized name: acetaminophen Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet acetaminophen 1000 mg
Study: 10761164
Drug: Both acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both acetaminophen formulations
Study: 9204788
Drug: Preoperative acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative acetaminophen (15 mg/kg oral)
Study: 9204788
Drug: Postoperative acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative acetaminophen (20 mg/kg rectal)
Study: 31023524
Drug: Metronomic capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic capecitabine (625 mg/m2 twice per day) with cyclophosphamide (50 mg/d)
Study: 26270199
Drug: HeProCalc program
Approvals — FDA: no, EMA: no, PMDA: no
Description: HeProCalc program for heparin and protamine dosing
Study: 26270199
Drug: Traditional heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional heparin and protamine dosing based on body weight
Study: 24618345
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (spinal manipulation, spinal mobilization, stretching and massage)
Study: 24618345
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy excluding spinal manipulation
Study: 24618345
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy excluding stretching
Study: 24618345
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (all groups)
Study: 20571294
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg IV before anesthesia)
Study: 20571294
Drug: Ketolgan (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketolgan (30 mg IV before anesthesia)
Study: 8719981
Drug: Perfusion scintigraphy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion scintigraphy in combination with ventilation studies
Study: 30935375
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of nonavalent HPV vaccine (GARDASIL 9)
Study: 24150660
Drug: Combination acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination acetaminophen (48 mg·kg(‐1)·day(‐1)) and ibuprofen (24 mg·kg(‐1)·day(‐1))
Study: 24150660
Drug: Acetaminophen alone
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen alone (48 mg·kg(‐1)·day(‐1))
Study: 24150660
Drug: Ibuprofen alone
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen alone (24 mg·kg(‐1)·day(‐1))
Study: 21341925
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (TN) 0-, 7-, 14-, or 21-mg doses
Study: 21341925
Drug: Smoking (independent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking (independent of TN dose)
Study: 11188776
Drug: IVIG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG treatment (immunoglobulin 10% 1 g/kg bodyweight)
Study: 11188776
Drug: Placebo (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.1 g albumin/vial)
Study: 9538657
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 80 mg sotalol
Study: 9538657
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 160 mg sotalol
Study: 9538657
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of sotalol
Study: 26227494
Drug: Diaphragm biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragm biofeedback training (DBT) + rabeprazole proton pump inhibitor (PPI)
Study: 24745020
Drug: Preemptive thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive thoracic epidural analgesia (TEA) administered as a bolus before surgical incision and continued until the end of surgery.
Study: 22697440
Drug: Transdiagnostic cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic cognitive-behavioral treatments (CBT) for anxiety disorders, 12-week duration
Study: 18973896
Drug: Cyclic oral
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic oral contraceptive therapy (low-dose, monophasic OCP for 24 months)
Study: 18973896
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral contraceptive therapy (low-dose, monophasic OCP for 24 months)
Study: 18973896
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (nonusers)
Study: 18928120
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (oral nylestriol, 2 mg/time, twice a month for 3 months, with medroxyprogesterone from the third month)
Study: 15970467
Drug: Psychiatric case
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychiatric case management (exact details of dosage and duration not available)
Study: 12490113
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir at 300 mg/day for 1 year (prophylaxis group)
Study: 9531028
Drug: Dalteparin, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin, 120 IU/kg bw twice daily for 5-8 days and 7,500 IU once daily for 35-40 days
Study: 9531028
Drug: Dalteparin, lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin, lower dose after initial high dose
Study: 23736109
Drug: Antihypertensive medications
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medications (average of 1.7 medications)
Study: 12612295
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg + inhaled budesonide 800 microg/day
Study: 12612295
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose inhaled budesonide 1600 microg/day
Study: 10832071
Drug: CoQ(10) supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ(10) supplementation (50 mg three times daily)
Study: 8194411
Drug: Manual injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual injection technique
Study: 31209657
Drug: Venetoclax in
Normalized name: Product containing venetoclax in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax in combination with Rituximab
Study: 25613938
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bevacizumab (IVB) at 0.625 mg per eye per dose
Study: 25613938
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bevacizumab (IVB) at 0.25 mg per eye per dose
Study: 21807052
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg dose of parvovirus B19 recombinant capsid
Study: 21807052
Drug: 2.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 μg dose of recombinant capsid with MF59
Study: 21807052
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg dose of recombinant capsid with MF59
Study: 15744699
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg once-daily subcutaneous regimen starting postoperatively
Study: 11120907
Drug: Erythromycin (1-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (1-100 microg/ml)
Study: 3791269
Drug: Methylphenidate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (10 mg with breakfast and 5 mg with lunch for 3 days)
Study: 29442148
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg maintenance dose (MD)
Study: 29442148
Drug: Routine clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine clinical dosage regimen (180 mg LD, 90 mg MD)